Overview
Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse. The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.
Background
Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse. The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.
Indication
For the treatment of Attention Deficit Disorder with Hyperactivity (ADHD) and exogenous obesity.
Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy
- Refractory exogenous obesity
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/05/25 | Early Phase 1 | Not yet recruiting | |||
2024/12/06 | Phase 2 | Not yet recruiting | |||
2023/03/24 | Phase 2 | Not yet recruiting | Carolyn Rodriguez | ||
2022/05/18 | Early Phase 1 | Completed | |||
2021/08/12 | Early Phase 1 | Completed | |||
2020/11/24 | Early Phase 1 | Completed | |||
2020/11/04 | Phase 1 | Recruiting | |||
2019/11/26 | Phase 1 | Completed | |||
2019/06/04 | Phase 4 | Completed | |||
2019/01/31 | Phase 4 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Mayne Pharma Commercial LLC | 68308-115 | ORAL | 5 mg in 1 1 | 7/5/2023 | |
| Key Therapeutics | 70868-820 | ORAL | 5 mg in 1 1 | 9/7/2022 | |
| Hikma Pharmaceuticals USA Inc. | 0054-0389 | ORAL | 5 mg in 1 1 | 4/7/2022 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||